中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2010年
22期
24-26
,共3页
黄芪%肾功能衰竭,慢性%促红细胞生成素%肾透析%红细胞免疫功能
黃芪%腎功能衰竭,慢性%促紅細胞生成素%腎透析%紅細胞免疫功能
황기%신공능쇠갈,만성%촉홍세포생성소%신투석%홍세포면역공능
Astrngahis membranaceus%Kidney failure,chronic%Recombinant human erythropoietin%Renal dialysis%Erythrocyte immune function
目的 观察黄芪注射液联合重组人促红细胞生成素(rHuEPO)对血液透析患者红细胞免疫功能的影响.方法 51例慢性肾衰竭尿毒症行血液透析维持治疗的患者,按随机数字表法分为治疗组(26例)与对照组(25例).治疗组在透析液A液中加入黄芪注射液1 ml/kg,对照组不使用黄芪注射液.测定治疗前后IgG、IgA、IgM、红细胞C3b受体花环率(RBC-C3bRR)、红细胞免疫复合物花环率(RBC-ICR)、CD35阳性红细胞百分率、红细胞超氧化物歧化酶(SOD)水平.结果 治疗8周后,治疗组IgG、IgA、IgM水平及对照组IgG、IgA水平显著高于治疗前(P<0.01);治疗组治疗8周后IgM水平为(2.03±0.73)g/L,与对照组比较差异有统计学意义(P<0.05).两组RBC-C3bRR、CD35阳性红细胞百分率、SOD水平治疗8周后显著高于治疗前,RBC-ICR水平显著低于治疗前(P<0.05);治疗组治疗8周后,RBC-C3bRR为(10.85±2.31)%,显著高于对照组,RBC-ICR为(5.34±1.91)%,显著低于对照组(P<0.05).结论 黄芪注射液联合rHuEPO可提高血液透析患者血清免疫球蛋白水平,提高红细胞免疫功能,较单用r-HuEPO效果更好.
目的 觀察黃芪註射液聯閤重組人促紅細胞生成素(rHuEPO)對血液透析患者紅細胞免疫功能的影響.方法 51例慢性腎衰竭尿毒癥行血液透析維持治療的患者,按隨機數字錶法分為治療組(26例)與對照組(25例).治療組在透析液A液中加入黃芪註射液1 ml/kg,對照組不使用黃芪註射液.測定治療前後IgG、IgA、IgM、紅細胞C3b受體花環率(RBC-C3bRR)、紅細胞免疫複閤物花環率(RBC-ICR)、CD35暘性紅細胞百分率、紅細胞超氧化物歧化酶(SOD)水平.結果 治療8週後,治療組IgG、IgA、IgM水平及對照組IgG、IgA水平顯著高于治療前(P<0.01);治療組治療8週後IgM水平為(2.03±0.73)g/L,與對照組比較差異有統計學意義(P<0.05).兩組RBC-C3bRR、CD35暘性紅細胞百分率、SOD水平治療8週後顯著高于治療前,RBC-ICR水平顯著低于治療前(P<0.05);治療組治療8週後,RBC-C3bRR為(10.85±2.31)%,顯著高于對照組,RBC-ICR為(5.34±1.91)%,顯著低于對照組(P<0.05).結論 黃芪註射液聯閤rHuEPO可提高血液透析患者血清免疫毬蛋白水平,提高紅細胞免疫功能,較單用r-HuEPO效果更好.
목적 관찰황기주사액연합중조인촉홍세포생성소(rHuEPO)대혈액투석환자홍세포면역공능적영향.방법 51례만성신쇠갈뇨독증행혈액투석유지치료적환자,안수궤수자표법분위치료조(26례)여대조조(25례).치료조재투석액A액중가입황기주사액1 ml/kg,대조조불사용황기주사액.측정치료전후IgG、IgA、IgM、홍세포C3b수체화배솔(RBC-C3bRR)、홍세포면역복합물화배솔(RBC-ICR)、CD35양성홍세포백분솔、홍세포초양화물기화매(SOD)수평.결과 치료8주후,치료조IgG、IgA、IgM수평급대조조IgG、IgA수평현저고우치료전(P<0.01);치료조치료8주후IgM수평위(2.03±0.73)g/L,여대조조비교차이유통계학의의(P<0.05).량조RBC-C3bRR、CD35양성홍세포백분솔、SOD수평치료8주후현저고우치료전,RBC-ICR수평현저저우치료전(P<0.05);치료조치료8주후,RBC-C3bRR위(10.85±2.31)%,현저고우대조조,RBC-ICR위(5.34±1.91)%,현저저우대조조(P<0.05).결론 황기주사액연합rHuEPO가제고혈액투석환자혈청면역구단백수평,제고홍세포면역공능,교단용r-HuEPO효과경호.
Objective To investigate the effects of astragalus membranaceus parenteral solution combined with recombinant human erythropietin (rHuEPO) on erythrocyte immunity function in patients with hemodialysis. Methods Fifty-one patients of chronic renal failure(CRF) with hemodialysis were divided into 2 groups randomly according to whether treated with astragalus membranaceus parenteral solution or not(therapeutic group, was 26 cases and control group was 25 cases). IgG, IgA, IgM, RBC-C3b,RR,RBC-ICR, erythrocyte percentage of CD35 positive and SOD was measured before treatment and 8 weeks after treatment. Results After 8 weeks' treatment, IgG,IgA,IgM levels in therapeutic group and IgG,IgA levels in control group were higher than those before treatment(P < 0.01 ). IgM [ (2.03±0.73 ) g/L ] was higher than that in control group (P< 0.05). RBC-C3B,RR, erythrocyte percentage of CD35 positive and SOD were higher and RBC-ICR was lower than those before treatment in two groups (P < 0.05 ) ;compared with that in control group, RBC-C3b, RR was higher [(10.85±2.31 )% ] and RBC-ICR was lower [(5.34±1.91 )% ] (P < 0.05 ).Conclusion Astragalus membranaceus parenteral solution combined with rHuEPO is superior to improve CRF patients' levels of immune globulin and erythrecyte immunity function.
